Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. (NYSE American: DSS) generates news across a wide range of sectors, reflecting its role as a multinational company with diversified business lines in packaging, biohealth innovation, financial services, alternative trading, and real estate. The company’s press releases and regulatory disclosures highlight strategic transactions, capital markets developments, operational milestones, and portfolio optimization efforts.
News about DSS often covers corporate strategy and portfolio management, including spin-offs, asset sales, and transactions involving key subsidiaries. Examples include the sale of the Celios air purification asset to Impact BioMedical Inc., as well as a definitive merger agreement under which Impact BioMedical will be acquired through a reverse merger with Dr. Ashleys Limited, resulting in a new public company. These items illustrate DSS’s stated approach of unlocking value by advancing subsidiaries toward independent public listings and other exit opportunities.
Investors and followers of DSS can also expect updates on financial performance and corporate actions. The company reports on revenue trends, cash flow improvements, debt reduction, and asset monetization, such as the sale of a real estate facility and growth in rental income. Leadership communications, including letters to shareholders and announcements of executive appointments, provide additional context on strategic priorities, cost reduction initiatives, and the focus on core growth verticals.
Because DSS has subsidiaries in securities and investment management, its news flow includes developments at entities like Sentinel Brokers Company, Inc. and AmericaFirst Funds. These updates may involve regulatory approvals, such as FINRA authorization for underwriting activities, changes to mutual fund boards, and expansion of capital markets capabilities. For a comprehensive view of DSS-related developments, readers can use this news page to follow corporate strategy, subsidiary activity, and key financial and regulatory events over time.
Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced promising results from clinical tests of its 3FDB (DEET Booster) technology aimed at enhancing mosquito repellents. Conducted in collaboration with Global Research and Discovery Group (GRDG), the tests demonstrated significant improvement in mosquito repellency rates, outperforming DEET alone. The tests revealed a 98% repellency rate after 3 hours with a 10% 3FDB and 5% DEET mix. The results indicate potential applications in personal care products and underscore the technology's capability to address mosquito-borne diseases.
Document Security Systems, Inc. (DSS) promoted Todd D. Macko to Chief Financial Officer effective August 16, 2021. With over 25 years of public and corporate accounting experience, Macko previously served as Vice President of Finance at DSS. His expertise includes financial planning, budgeting, and mergers and acquisitions. CEO Frank D. Heuszel expressed confidence in Macko's ability to support the company's long-term strategy. DSS operates in multiple sectors including blockchain security and renewable energy, focusing on shareholder value through potential spin-offs of subsidiaries.
DSS, a multinational company, announced a $1 million equity investment in Vivacitas Oncology, a clinical-stage firm focused on difficult-to-treat cancers. This investment, made through DSS Biomedical, highlights DSS's commitment to enhancing human healthcare. Vivacitas's lead candidate, AR-67, shows promise in treating cancers resistant to current therapies, with clinical data indicating potential improvements in progression-free survival for glioblastoma patients while reducing severe side effects. The CEO of DSS expressed optimism about the strategic investment.
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced a collaboration with Thomas Swan Co. to research Procombin, a plant-based preservation booster. This partnership aims to test Procombin's effectiveness in extending the shelf life of consumer products including personal care and cleaning items. Daryl Thompson emphasized the project’s potential to enhance product quality globally. Thomas Swan, established in 1926, specializes in custom chemical research. The development of Procombin represents a significant step towards sustainable preservation solutions.
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced the issuance of Patent # 11,033,528 for its antiviral compound Equivir on June 15, 2021. This patent follows the initial patent granted in 2019. Equivir has shown positive pre-clinical results against viral infections including Ebola and Rhinovirus. The company is pursuing a third patent and aims to explore its potential in various antiviral applications, enhancing its intellectual property portfolio.
Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced major updates on its research projects aimed at addressing global challenges in biotechnology. Key collaborations and advancements were highlighted, including the Procombin study to improve antibiotics and the CRST-1 molecule, which shows promising results in cancer treatment. The company is also exploring global licensing for several products, such as Equivir and Linebacker. This strategic focus on innovation positions Impact Biomedical as a potential leader in the biotech industry.
Document Security Systems (DSS) announced the launch of Liquid Value Asset Management Limited (LVAM) through its subsidiary, DSS Financial Management Inc. This fund management company, based in Hong Kong, will focus on algorithmic trading across various financial instruments. The team, including former Societe Generale and Citadel professionals, boasts a track record of 20% annual returns and a Sharpe ratio above 2.0. CEO Frank D. Heuszel expressed confidence in rapidly growing LVAM's trading assets to over $1 billion.
Document Security Systems (DSS) has announced a significant expansion in its investment in American Medical REIT (AMRE) through a $2.6 million share purchase, increasing its ownership from 52% to 99%. This investment will fund the acquisition of Ivy Brook Medical Center in Shelton, Connecticut, a prestigious 40,000 square-foot facility. CEO Frank Heuszel highlighted the resilience of the health services real estate sector, citing nearly 100% rent collection rates compared to pre-COVID levels. DSS aims to leverage its expertise to enhance AMRE's portfolio.
Aegis Capital Corp. acted as the Sole Bookrunner for a $50 million public offering of common stock for Document Security Systems, Inc. (DSS), including the exercise of the over-allotment option. This offering is aimed at securing capital for the company's diverse operations, which encompass brand protection technology, blockchain security, and direct marketing, among others. DSS's model includes strategically spinning out subsidiaries through IPOs, potentially enhancing shareholder value.
Document Security Systems, Inc. (NYSE American: DSS) announced the closing of a public offering generating $50.025 million in gross proceeds. The offering consisted of 29 million shares at $1.50 per share, with an additional 4.35 million shares sold via the underwriters' over-allotment option. These funds will support growth in new business lines, acquisitions, and general corporate needs. The offering was executed under a shelf registration statement effective as of June 7, 2021.